{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:28:23Z","timestamp":1792218503070,"version":"4.4.0"},"reference-count":86,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T00:00:00Z","timestamp":1444694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title\/><jats:p>The myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal myeloid malignancies characterized by multilineage cytopenias, recurrent cytogenetic abnormalities, and risk of progression to acute myeloid leukemia (AML). AML, which can occur de novo as well as secondary to MDS, is characterized by malignant clones of myeloid lineage in the bone marrow and peripheral blood, with dissemination into tissues. The cytidine nucleoside analog and epigenetic modifier azacitidine is approved in the U.S. for the treatment of all French-American-British subtypes of MDS and in many countries for the treatment of AML with 20%\u201330% blasts and multilineage dysplasia according to the World Health Organization classification. Benefits of azacitidine treatment of patients with AML with &amp;gt;30% blasts have also been shown in a recent phase III trial. Oral administration of azacitidine may enhance patient convenience, eliminate injection-site reactions, allow for alternative dosing and scheduling, and enable long-term treatment. Phase I studies with oral azacitidine (CC-486) have shown biological activity, clinical responses, and tolerability in patients with MDS and AML. Extended dosing schedules of oral azacitidine (for 14 or 21 days of 28-day cycles) are currently under investigation as frontline therapy in patients with lower risk MDS, as maintenance therapy for patients with AML not eligible for stem cell transplant, and as maintenance therapy for patients with MDS or AML following stem cell transplant. This review presents clinical data supporting the use of injectable azacitidine in MDS and AML and examines the rationale for and results of the clinical development of oral azacitidine.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2015-0165","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T02:09:05Z","timestamp":1444788545000},"page":"1404-1412","source":"Crossref","is-referenced-by-count":43,"title":["Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia"],"prefix":"10.1093","volume":"20","author":[{"given":"Christopher R.","family":"Cogle","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart L.","family":"Scott","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Boyd","sequence":"additional","affiliation":[{"name":"North Star Lodge Cancer Center, Yakima, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,10,13]]},"reference":[{"key":"2021122309363767100_B1","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122309363767100_B2","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"2021122309363767100_B3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"2021122309363767100_B4","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ccr.2014.03.036","article-title":"Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo","volume":"25","author":"Woll","year":"2014","journal-title":"Cancer Cell"},{"key":"2021122309363767100_B5","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMp048266","article-title":"Myelodysplastic syndromes\u2013coping with ineffective hematopoiesis","volume":"352","author":"Cazzola","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122309363767100_B6","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199905273402107","article-title":"Myelodysplasia","volume":"340","author":"Heaney","year":"1999","journal-title":"N Engl J Med"},{"key":"2021122309363767100_B7","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","article-title":"New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge","volume":"30","author":"Schanz","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309363767100_B8","volume-title":"NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): Myelodysplastic syndromes, version 1.2016","year":"2015"},{"key":"2021122309363767100_B9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ng.1009","article-title":"Dnmt3a is essential for hematopoietic stem cell differentiation","volume":"44","author":"Challen","year":"2012","journal-title":"Nat Genet"},{"key":"2021122309363767100_B10","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/leu.2011.44","article-title":"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes","volume":"25","author":"Walter","year":"2011","journal-title":"Leukemia"},{"key":"2021122309363767100_B11","doi-asserted-by":"crossref","first-page":"14566","DOI":"10.1073\/pnas.1112317108","article-title":"Ten-eleven-translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice","volume":"108","author":"Ko","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122309363767100_B12","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/cncr.22570","article-title":"Myelodysplastic syndromes: Incidence and survival in the United States","volume":"109","author":"Ma","year":"2007","journal-title":"Cancer"},{"key":"2021122309363767100_B13","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"2021122309363767100_B14","volume-title":"Previous version: SEER cancer statistics review, 1975-2011","year":"2015"},{"key":"2021122309363767100_B15","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"2021122309363767100_B16","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1182\/blood-2011-02-337964","article-title":"Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: High number of uncaptured cases by cancer registries","volume":"117","author":"Cogle","year":"2011","journal-title":"Blood"},{"key":"2021122309363767100_B17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1158\/1055-9965.EPI-11-1087","article-title":"Underreporting of myeloid malignancies by United States cancer registries","volume":"21","author":"Craig","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122309363767100_B18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.leukres.2013.10.023","article-title":"High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment","volume":"38","author":"Cogle","year":"2014","journal-title":"Leuk Res"},{"key":"2021122309363767100_B19","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"2021122309363767100_B20","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2011.044602","article-title":"Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)","volume":"96","author":"Malcovati","year":"2011","journal-title":"Haematologica"},{"key":"2021122309363767100_B21","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"key":"2021122309363767100_B22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"2021122309363767100_B23","first-page":"1183","volume-title":"Williams Hematology","author":"Liesveld","year":"2005","edition":"7th ed."},{"key":"2021122309363767100_B24","first-page":"137","article-title":"The molecular pathology of acute myeloid leukemia","volume-title":"Hematology Am Soc Hematol Educ Program","author":"Licht","year":"2005"},{"key":"2021122309363767100_B25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"key":"2021122309363767100_B26","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/cncr.28129","article-title":"Outcome of older patients with acute myeloid leukemia: An analysis of SEER data over 3 decades","volume":"119","author":"Thein","year":"2013","journal-title":"Cancer"},{"key":"2021122309363767100_B27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"2021122309363767100_B28","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2141.2006.06314.x","article-title":"Guidelines on the management of acute myeloid leukaemia in adults","volume":"135","author":"Milligan","year":"2006","journal-title":"Br J Haematol"},{"key":"2021122309363767100_B29","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.2010.08470.x","article-title":"Acute myeloid leukaemia in the elderly: A review","volume":"152","author":"Pollyea","year":"2011","journal-title":"Br J Haematol"},{"key":"2021122309363767100_B30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0268-960X(98)90012-1","article-title":"Acute myeloid leukemia in the elderly","volume":"12","author":"Harousseau","year":"1998","journal-title":"Blood Rev"},{"key":"2021122309363767100_B31","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122309363767100_B32","volume-title":"Vidaza (azacitidine for injection) [package insert]","year":"2014"},{"key":"2021122309363767100_B33","volume-title":"Dacogen (decitabine) [package insert]","year":"2010"},{"key":"2021122309363767100_B34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2147\/tcrm.2006.2.4.377","article-title":"Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes","volume":"2","author":"Raj","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"2021122309363767100_B35","doi-asserted-by":"crossref","first-page":"e9001","DOI":"10.1371\/journal.pone.0009001","article-title":"A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines","volume":"5","author":"Hollenbach","year":"2010","journal-title":"PLoS One"},{"key":"2021122309363767100_B36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","article-title":"FDA drug approval summary: Azacitidine (5-azacytidine, Vidaza) for injectable suspension","volume":"10","author":"Kaminskas","year":"2005","journal-title":"The Oncologist"},{"key":"2021122309363767100_B37","first-page":"959","article-title":"Biochemistry of azacitidine: A review","volume":"71","author":"Glover","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"2021122309363767100_B38","volume-title":"Vidaza (azacitidine for injection) [package insert]","year":"2015"},{"key":"2021122309363767100_B39","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.leukres.2014.03.004","article-title":"Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia","volume":"38","author":"Garc\u00eda-Delgado","year":"2014","journal-title":"Leuk Res"},{"key":"2021122309363767100_B40","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2008.17.1058","article-title":"Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes","volume":"27","author":"Lyons","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122309363767100_B41","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ajh.21482","article-title":"A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes","volume":"84","author":"Martin","year":"2009","journal-title":"Am J Hematol"},{"key":"2021122309363767100_B42","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122309363767100_B43","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"2021122309363767100_B44","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.2012.074831","article-title":"A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial","volume":"98","author":"Gore","year":"2013","journal-title":"Haematologica"},{"key":"2021122309363767100_B45","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122309363767100_B46","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1002\/cncr.25774","article-title":"Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes","volume":"117","author":"Silverman","year":"2011","journal-title":"Cancer"},{"key":"2021122309363767100_B47","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1182\/blood-2013-08-496935","article-title":"How we treat higher-risk myelodysplastic syndromes","volume":"123","author":"Sekeres","year":"2014","journal-title":"Blood"},{"key":"2021122309363767100_B48","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.clml.2013.07.007","article-title":"Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure","volume":"13","author":"Duong","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021122309363767100_B49","doi-asserted-by":"crossref","first-page":"3273a","DOI":"10.1182\/blood.V124.21.3273.3273","article-title":"Outcomes of patients with myelodysplastic syndromes (MDS) who achieve stable disease after treatment with hypomethylating agents","volume":"124","author":"Nazha","year":"2014","journal-title":"Blood"},{"key":"2021122309363767100_B50","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1080\/10428190701882146","article-title":"Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine","volume":"49","author":"Borthakur","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"2021122309363767100_B51","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Pr\u00e9bet","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122309363767100_B52","doi-asserted-by":"crossref","first-page":"2796a","DOI":"10.1182\/blood.V122.21.2796.2796","article-title":"Treatment with decitabine (DAC) after azacitidine (AZA) failure in high risk myelodysplastic syndrome (MDS) and advanced chronic myelomonocytic leukemia (CMML)","volume":"122","author":"Braun","year":"2013","journal-title":"Blood"},{"key":"2021122309363767100_B53","doi-asserted-by":"crossref","first-page":"3858a","DOI":"10.1182\/blood.V120.21.3858.3858","article-title":"Lack of response of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) to decitabine after failure of azacitidine","volume":"120","author":"Bhatnagar","year":"2012","journal-title":"Blood"},{"key":"2021122309363767100_B54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1600-0609.2010.01456.x","article-title":"Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine","volume":"85","author":"Santini","year":"2010","journal-title":"Eur J Haematol"},{"key":"2021122309363767100_B55","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"2021122309363767100_B56","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/leu.2008.145","article-title":"A pilot pharmacokinetic study of oral azacitidine","volume":"22","author":"Garcia-Manero","year":"2008","journal-title":"Leukemia"},{"key":"2021122309363767100_B57","doi-asserted-by":"crossref","first-page":"603a","DOI":"10.1182\/blood.V116.21.603.603","article-title":"Evaluation of oral azacitidine using extended treatment schedules: A phase I study","volume":"116","author":"Garcia-Manero","year":"2010","journal-title":"Blood"},{"key":"2021122309363767100_B58","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ajh.2830370207","article-title":"Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes","volume":"37","author":"Chitambar","year":"1991","journal-title":"Am J Hematol"},{"key":"2021122309363767100_B59","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/1097-0142(19810401)47:7<1739::AID-CNCR2820470702>3.0.CO;2-2","article-title":"Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: A Southwest Oncology Group Study","volume":"47","author":"Saiki","year":"1981","journal-title":"Cancer"},{"key":"2021122309363767100_B60","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1002\/1097-0142(197811)42:5<2111::AID-CNCR2820420505>3.0.CO;2-I","article-title":"5-Azacytidine in acute leukemia","volume":"42","author":"Saiki","year":"1978","journal-title":"Cancer"},{"key":"2021122309363767100_B61","doi-asserted-by":"crossref","first-page":"237","DOI":"10.7326\/0003-4819-85-2-237","article-title":"5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia","volume":"85","author":"Von Hoff","year":"1976","journal-title":"Ann Intern Med"},{"key":"2021122309363767100_B62","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1128\/MCB.01799-07","article-title":"DNA methylation inhibitor 5-Aza-2\u2032-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B","volume":"28","author":"Palii","year":"2008","journal-title":"Mol Cell Biol"},{"key":"2021122309363767100_B63","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)15093-1","article-title":"Long term instability and molecular mechanism of 5-azacytidine-induced DNA hypomethylation in normal and neoplastic tissues in vivo","volume":"26","author":"Lu","year":"1984","journal-title":"Mol Pharmacol"},{"key":"2021122309363767100_B64","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-134-7-200104030-00011","article-title":"Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications","volume":"134","author":"Santini","year":"2001","journal-title":"Ann Intern Med"},{"key":"2021122309363767100_B65","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/0091270004271947","article-title":"Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes","volume":"45","author":"Marcucci","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"2021122309363767100_B66","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","article-title":"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122309363767100_B67","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/jcph.251","article-title":"Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies","volume":"54","author":"Laille","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"2021122309363767100_B68","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.leu.2405070","article-title":"A prognostic score for patients with lower risk myelodysplastic syndrome","volume":"22","author":"Garcia-Manero","year":"2008","journal-title":"Leukemia"},{"issue":"424a","key":"2021122309363767100_B69","article-title":"Safety and efficacy of oral azacitidine (CC-486) administered in extended treatment schedules to patients with lower-risk myelodysplastic syndromes","volume":"120","author":"Garcia-Manero","year":"2012","journal-title":"Blood"},{"key":"2021122309363767100_B70","volume-title":"NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): Acute myeloid leukemia, version 1.2015","year":"2015"},{"issue":"1546a","key":"2021122309363767100_B71","article-title":"Oral azacitidine (AZA) activity in patients with acute myelogenous leukemia (AML)","volume":"118","author":"Gore","year":"2011","journal-title":"Blood"},{"key":"2021122309363767100_B72","doi-asserted-by":"crossref","first-page":"1337a","DOI":"10.1182\/blood.V120.21.1337.1337","article-title":"Extended dosing of oral azacitidine (CC-486) for 14 and 21 days provides more effective methylation reversal than a 7-day schedule","volume":"120","author":"Laille","year":"2012","journal-title":"Blood"},{"key":"2021122309363767100_B73","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3324\/haematol.2013.099549","article-title":"Why methylation is not a marker predictive of response to hypomethylating agents","volume":"99","author":"Voso","year":"2014","journal-title":"Haematologica"},{"key":"2021122309363767100_B74","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/leu.2011.71","article-title":"Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias","volume":"25","author":"Itzykson","year":"2011","journal-title":"Leukemia"},{"key":"2021122309363767100_B75","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"key":"2021122309363767100_B76","doi-asserted-by":"crossref","first-page":"E77","DOI":"10.1002\/ajh.23965","article-title":"Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia","volume":"90","author":"Emadi","year":"2015","journal-title":"Am J Hematol"},{"key":"2021122309363767100_B77","volume-title":"The efficacy and safety of oral azacitidine plus best supportive care versus placebo and best supportive care in subjects with red blood cell (RBC) transfusion-dependent anemia and thrombocytopenia due to International Prognostic Scoring System (IPSS) low risk myelodysplastic syndrome (MDS)","year":"2015"},{"key":"2021122309363767100_B78","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/asheducation.V2012.1.43.3798183","article-title":"The prevalent predicament of relapsed acute myeloid leukemia","volume":"2012","author":"Szer","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122309363767100_B79","volume-title":"Efficacy of oral azacitidine plus best supportive care as maintenance therapy in subjects with acute myeloid leukemia in complete remission (QUAZAR AML-001)","year":"2015"},{"issue":"suppl 5","key":"2021122309363767100_B80","doi-asserted-by":"crossref","first-page":"v158","DOI":"10.1093\/annonc\/mdq179","article-title":"Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Fey","year":"2010","journal-title":"Ann Oncol"},{"key":"2021122309363767100_B81","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev.med.051308.132852","article-title":"Myelodysplastic syndromes","volume":"61","author":"Scott","year":"2010","journal-title":"Annu Rev Med"},{"key":"2021122309363767100_B82","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1200\/JCO.1994.12.8.1710","article-title":"Leukemia: Management of relapse after allogeneic bone marrow transplantation","volume":"12","author":"Kumar","year":"1994","journal-title":"J Clin Oncol"},{"key":"2021122309363767100_B83","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2008-03-143735","article-title":"WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: A study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"112","author":"Alessandrino","year":"2008","journal-title":"Blood"},{"key":"2021122309363767100_B84","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2009.21.8073","article-title":"Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia","volume":"28","author":"Lim","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122309363767100_B85","first-page":"1997","article-title":"Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia","volume":"100","author":"Sierra","year":"2002","journal-title":"Blood"},{"key":"2021122309363767100_B86","volume-title":"Safety study of oral azacitidine (CC-486) as maintenance therapy after allogeneic hematopoietic stem cell transplantation in subjects with acute myeloid leukemia or myelodysplastic syndromes","year":"2015"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0165","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0165","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/12\/1404\/41870052\/oncolo_20_12_1404.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/12\/1404\/41870052\/oncolo_20_12_1404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T01:06:40Z","timestamp":1748653600000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/20\/12\/1404\/6399929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,13]]},"references-count":86,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,10,13]]},"published-print":{"date-parts":[[2015,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0165","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,12,1]]},"published":{"date-parts":[[2015,10,13]]}}}